Valneva COVID-19 vaccine
Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.[6][7][8]
In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do so.[3] It was approved for medical use in the European Union in June 2022.[2]
History[edit]
Clinical trials[edit]
Valneva COVID-19 vaccine completed phase I/II trial with 153 participants in the United Kingdom.[10][11] The trials were supported by the UK National Institute for Health Research and four British universities.[12]
In April 2021, Valneva COVID-19 vaccine commenced phase III trials with approximately 4,000 participants.[13] In August 2021, New Zealand was chosen for trialing on 300 adult volunteers, due to low case numbers and slow vaccine rollout.[14] Positive results for the phase III trials were reported in October 2021.[15]